These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25017515)

  • 41. Functional interplay between NF-κB-inducing kinase and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma.
    Mazzera L; Abeltino M; Lombardi G; Cantoni AM; Ria R; Ricca M; Saltarella I; Naponelli V; Rizzi FMA; Perris R; Corradi A; Vacca A; Bonati A; Lunghi P
    Haematologica; 2019 Dec; 104(12):2465-2481. PubMed ID: 30948493
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Myc proteins as therapeutic targets.
    Gustafson WC; Weiss WA
    Oncogene; 2010 Mar; 29(9):1249-59. PubMed ID: 20101214
    [TBL] [Abstract][Full Text] [Related]  

  • 43. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells.
    Yacoub A; Park MA; Hanna D; Hong Y; Mitchell C; Pandya AP; Harada H; Powis G; Chen CS; Koumenis C; Grant S; Dent P
    Mol Pharmacol; 2006 Aug; 70(2):589-603. PubMed ID: 16622074
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
    Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
    Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
    [TBL] [Abstract][Full Text] [Related]  

  • 45. OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms.
    Zhang S; Suvannasankha A; Crean CD; White VL; Johnson A; Chen CS; Farag SS
    Clin Cancer Res; 2007 Aug; 13(16):4750-8. PubMed ID: 17699852
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc.
    Sun Y; Liu PY; Scarlett CJ; Malyukova A; Liu B; Marshall GM; MacKenzie KL; Biankin AV; Liu T
    Oncogene; 2014 Jun; 33(23):2987-94. PubMed ID: 23812427
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
    Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
    Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.
    Veschi V; Petroni M; Cardinali B; Dominici C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Giannini G
    PLoS One; 2012; 7(11):e49139. PubMed ID: 23152863
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination.
    Wu X; Nelson M; Basu M; Srinivasan P; Lazarski C; Zhang P; Zheng P; Sandler AD
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757986
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
    Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
    J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN.
    Misawa A; Hosoi H; Tsuchiya K; Sugimoto T
    Int J Cancer; 2003 Mar; 104(2):233-7. PubMed ID: 12569580
    [TBL] [Abstract][Full Text] [Related]  

  • 53. OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma.
    Gao M; Yeh PY; Lu YS; Hsu CH; Chen KF; Lee WC; Feng WC; Chen CS; Kuo ML; Cheng AL
    Cancer Res; 2008 Nov; 68(22):9348-57. PubMed ID: 19010909
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors.
    Di Giulio S; Colicchia V; Pastorino F; Pedretti F; Fabretti F; Nicolis di Robilant V; Ramponi V; Scafetta G; Moretti M; Licursi V; Belardinilli F; Peruzzi G; Infante P; Goffredo BM; Coppa A; Canettieri G; Bartolazzi A; Ponzoni M; Giannini G; Petroni M
    Oncogene; 2021 Oct; 40(43):6143-6152. PubMed ID: 34508175
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
    Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
    Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FX11 inhibits aerobic glycolysis and growth of neuroblastoma cells.
    Rellinger EJ; Craig BT; Alvarez AL; Dusek HL; Kim KW; Qiao J; Chung DH
    Surgery; 2017 Mar; 161(3):747-752. PubMed ID: 27919448
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells.
    Čančer M; Drews LF; Bengtsson J; Bolin S; Rosén G; Westermark B; Nelander S; Forsberg-Nilsson K; Uhrbom L; Weishaupt H; Swartling FJ
    Cell Death Dis; 2019 Nov; 10(12):881. PubMed ID: 31754113
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma.
    Bogen D; Wei JS; Azorsa DO; Ormanoglu P; Buehler E; Guha R; Keller JM; Mathews Griner LA; Ferrer M; Song YK; Liao H; Mendoza A; Gryder BE; Sindri S; He J; Wen X; Zhang S; Shern JF; Yohe ME; Taschner-Mandl S; Shohet JM; Thomas CJ; Martin SE; Ambros PF; Khan J
    Oncotarget; 2015 Nov; 6(34):35247-62. PubMed ID: 26497213
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells.
    Chayka O; D'Acunto CW; Middleton O; Arab M; Sala A
    J Biol Chem; 2015 Jan; 290(4):2198-212. PubMed ID: 25477524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.